Tokyo, Aug. 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058737) titled 'Prospective observational study to investigate the relationships between pharmacokinetics and therapeutic efficacy of deucravacitinib in patients with psoriasis' on Aug. 8.
Study Type:
Observational
Primary Sponsor:
Institute - other
Condition:
Condition - psoriasis
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - This study investigates the relationships between plasma concentration and efficacy of deucravacitinib in patients with psoriasis.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - Those who provided a written consent to participate in the study or whose family provided a written consent to participate in the study
Key exclusion criteria - 1. Patients with severe infection
2. Patients with active tuberculosis
3. Patients with severe hepatic impairment (Child-Pugh classification of C)
4. Pregnant, breastfeeding or expecting women
5. Others deemed inappropriate by the attending physician
Target Size - 90
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2024 Year 10 Month 15 Day
Date of IRB - 2024 Year 09 Month 24 Day
Anticipated trial start date - 2024 Year 12 Month 01 Day
Last follow-up date - 2027 Year 10 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064442
Disclaimer: Curated by HT Syndication.
